The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.

@article{Otte2003TheMR,
  title={The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.},
  author={C. Otte and H. Jahn and A. Yassouridis and J. Arlt and N. Stober and P. Maass and K. Wiedemann and M. Kellner},
  journal={Life sciences},
  year={2003},
  volume={73 14},
  pages={
          1835-45
        }
}
  • C. Otte, H. Jahn, +5 authors M. Kellner
  • Published 2003
  • Medicine
  • Life sciences
  • Whereas animal studies have shown a clear inhibitory effect of hippocampal mineralocorticoid receptors (MR) on hypothalamic-pituitary-adrenal (HPA) axis activity, investigations in humans revealed equivocal results. To further clarify the influence of MR in HPA activity we studied 10 healthy men during the circadian nadir of HPA activity (14:00 to 21:00) after pre-treatment with 3 g metyrapone to minimize the impact of basal endogenous cortisol secretion. On three separate occasions, in a… CONTINUE READING
    50 Citations
    The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic–pituitary–adrenal (HPA) axis in humans
    • 11
    • Highly Influenced
    Role of mineralocorticoid receptors on the hypothalamus–pituitary–adrenal axis in humans
    • 52

    References

    SHOWING 1-10 OF 40 REFERENCES
    Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans.
    • 54
    • PDF
    The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans.
    • 121
    • PDF
    Mineralocorticoid receptor function in major depression.
    • 183
    • PDF